ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Topotecan

Also written as “topotecan”, “topotecan hydrochloride” and “Topotecan/Docetaxel combination”.

Its studies are mostly in Small Cell Lung Carcinoma · Ovarian Neoplasms · Neoplasms · Carcinoma, Non-Small-Cell Lung · Endometrial Neoplasms, led by 15 companies.

Drug pageTopotecan: every studyMany companies study it; this page follows only the 33 they lead. All 251 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Aug 14, 200233 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only180 open or runningphase 3since Aug 14, 2002Nov 2, 1999none ahead
Bristol-Myers Squibbits history only20 open or runningphase 2since Sep 10, 2005Sep 10, 2005none ahead
AbbVieits history only10 open or runningphase 3since Dec 10, 2015Dec 10, 2015none ahead
Advenchen Laboratoriesits history only11 open or runningphase 3since Aug 28, 2015Aug 28, 2015none ahead
Ascenta Therapeuticsits history only10 open or runningphase 2since Nov 7, 2006Nov 7, 2006none ahead
AstraZeneca10 open or runningphase 2since Apr 10, 2001Apr 10, 2001none ahead
BioNTechits history only11 open or runningphase 2since Jun 3, 2024Jun 3, 2024Jun 2027phase 2 · NCT06449209
Chong Kun Dang Pharmaceuticalits history only10 open or runningphase 2since Mar 6, 2012Mar 6, 2012none ahead
Gilead Sciencesits history only11 open or runningphase 3since Jan 24, 2025Jan 24, 2025Oct 2029phase 3 · NCT06801834
Hoffmann-La Rocheits history only10 open or runningphase 3since Sep 11, 2012Sep 11, 2012none ahead

Also a collaborator on its studies: Eisai, Baili-Bio (Chengdu) Pharmaceutical and Prologue Research International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 10, 2001First study: phase 2 study in Fallopian Tube NeoplasmsFirst studyNCT00014690 · United States

TargetBeta

TOP1 →read by rule
“DNA topoisomerase I inhibitor”ChEMBL 37, by rule

Other programs on TOP1

ProgramCompanyFurthest phaseStudies
irinotecan sucrosofateruleCSPC Pharmaceutical Groupphase 320

Studies

The one study AstraZeneca leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00014690Fallopian Tube Neoplasms · United States2Completed

How it is read

Names in the registry

  • “Topotecan”, 15 entries
  • “topotecan”, 11 entries
  • “topotecan hydrochloride”, 2 entries
  • “Topotecan/Docetaxel combination”, 1 entry
  • “Topotecan (Chemotherapy)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.